Adalimumab is a human recombinant mAb directed against the soluble and cell-bound forms of tumor necrosis factor-alpha (TNF-α). 18 It is approved for use in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, inflammatory bowel disease, and both the skin and joint manifestations of psoriasis.
Specification/Additional Details
- Mabura 40
- Hetero Healthcare
- 40 mg / 0.8 ml
- Pre Filled Syringe
- Prescription
Reviews
There are no reviews yet.